{"ticker": {"uuid": "2f78b92c-4206-4124-9eba-515571ad8dd1", "symbol": "ABCL", "name": "Abcellera Biologics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "ABCL|Abcellera Biologics Inc|Price:5.665|Chg%:-0.065", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1oTUcycGo4dE5IZXV3aGstaHV2RkdlV3NNOHFDZDZoR09USTlXelJfSmNOcWhSdFJHc1pHdHVpMkY3Rk55Yks5TmZzSWdMd1NCYXN1bVp5Tk9lZw?oc=5", "source_name": "TradingKey", "published_at": "2026-07-24T09:10:31+00:00", "published_display": "24 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abcellera Biologics, Inc. (ABCL) Q1 2025 Earnings Report - Results, Call & Slides", "summary": "Abcellera Biologics (ABCL) released its Q1 2025 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -$0.15 against a consensus of -$0.14, and actual revenue of $4.24 million versus an expected $7.24 million, representing a 57.45% year", "url": "https://www.tipranks.com/stocks/abcl/earnings/q1-2025-report", "source_name": "TipRanks", "published_at": "2026-07-23T01:10:56", "published_display": "23 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abcellera Biologics, Inc. (8QQ) Q3 2025 Earnings Report - Results, Call & Slides", "summary": "Abcellera Biologics (8QQ) released its Q3 2025 earnings report, missing consensus EPS estimates by \u20ac0.04 with an actual EPS of -\u20ac0.17 versus an expected -\u20ac0.12. However, the company beat revenue expectations, reporting \u20ac7.85M against an expected \u20ac5.55M, representing a 37.62% year", "url": "https://www.tipranks.com/stocks/de:8qq/earnings/q3-2025-report", "source_name": "TipRanks", "published_at": "2026-07-21T23:09:40", "published_display": "21 Jul 2026 23:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abcellera Biologics, Inc. (8QQ) Q3 2024 Earnings Report - Results, Call & Slides", "summary": "Abcellera Biologics (8QQ) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -\u20ac0.15 against a consensus of -\u20ac0.11 and actual revenue of \u20ac5.70M compared to an expected \u20ac6.73M. The Q3 2024 earnings call was scheduled for No", "url": "https://www.tipranks.com/stocks/de:8qq/earnings/q3-2024-report", "source_name": "TipRanks", "published_at": "2026-07-21T22:41:04", "published_display": "21 Jul 2026 22:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does AbCellera\u2019s New Board Appointment Reframe Its Execution Story for Investors in ABCL?", "summary": "AbCellera Biologics announced the appointment of Lynn Seely, M.D., to its Board of Directors, bringing extensive experience in clinical development and commercialization, particularly in oncology. This appointment is expected to strengthen AbCellera's board-level expertise, align", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/does-abcelleras-new-board-appointment-reframe-its-execution", "source_name": "Simply Wall Street", "published_at": "2026-07-20T06:10:07", "published_display": "20 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11", "summary": "Cantor Fitzgerald has reiterated an Overweight rating and an $11.00 price target for AbCellera Biologics (NASDAQ:ABCL). The firm anticipates positive Phase 2 data for AbCellera's anti-NK3R antibody ABCL635 in Q3 2026, expecting favorable comparisons to approved inhibitors and a s", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-overweight-on-abcellera-stock-at-11-93CH-4798694", "source_name": "Investing.com", "published_at": "2026-07-18T14:40:27", "published_display": "18 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11 By Investing.com", "summary": "Cantor Fitzgerald has reiterated an Overweight rating and an $11 price target on AbCellera Biologics (NASDAQ:ABCL). The firm anticipates positive Phase 2 data for AbCellera's anti-NK3R antibody ABCL635 in treating vasomotor symptoms in menopause, projecting significant upside for", "url": "https://ng.investing.com/news/stock-market-news/cantor-fitzgerald-reiterates-overweight-on-abcellera-stock-at-11-93CH-2605417", "source_name": "Investing.com Nigeria", "published_at": "2026-07-18T02:39:24", "published_display": "18 Jul 2026 02:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFB5aUM2X0RTcUtleVByb05SSzAwVmRPWUxFZWJaZXgta2ZyU3VmSHY4UXFzZnd6UXppNzlNdDl3dzJyTFkwNWYyYlRJNnBIcXBqRW9mLTQ1S29Wd3c?oc=5", "source_name": "ChartMill", "published_at": "2026-07-18T00:24:07+00:00", "published_display": "18 Jul 2026 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13", "summary": "JonesTrading has reiterated its Buy rating for AbCellera Biologics (ABCL.US), maintaining a target price of $13. This indicates continued confidence from the analyst firm in the company's stock performance.", "url": "https://www.moomoo.com/news/post/73030276/jonestrading-maintains-abcellera-biologics-abclus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-16T14:10:55", "published_display": "16 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ABCL Stock Price and Chart \u2014 NASDAQ:ABCL", "summary": "This article provides an overview of AbCellera Biologics Inc. (ABCL) stock, including its current price, market capitalization, key financial stats, and recent performance. It highlights the company's role as an AI-biotech firm specializing in therapeutic antibody discovery and i", "url": "https://www.tradingview.com/symbols/NASDAQ-ABCL/", "source_name": "TradingView", "published_at": "2026-07-14T13:40:13", "published_display": "14 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Weekly Recap: Lynn Seely board appointment and Benchmark upgrade to Buy", "summary": "AbCellera Biologics (ABCL) has appointed Lynn Seely to its board as a Class III director, effective June 30, 2026. Concurrently, Benchmark upgraded the stock to Buy with an $11 target price. The company is set to report its Q2 2026 results on August 5, 2026, followed by an earnin", "url": "https://www.tradingview.com/news/tradingview:4d3fd946dd5a3:0-weekly-recap-lynn-seely-board-appointment-and-benchmark-upgrade-to-buy/", "source_name": "TradingView", "published_at": "2026-07-13T11:40:41", "published_display": "13 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AbCellera Biologics Stock (ABCL) Opinions on Jazz Partnership and Analyst Upgrade", "summary": "The article discusses positive sentiment surrounding AbCellera Biologics (ABCL) due to its partnership with Jazz Pharmaceuticals and a recent analyst upgrade. Key catalysts include upcoming Phase 2 data for ABCL635 and new executive hires. Insider buying activity and increased in", "url": "https://www.quiverquant.com/news/AbCellera+Biologics+Stock+%28ABCL%29+Opinions+on+Jazz+Partnership+and+Analyst+Upgrade", "source_name": "Quiver Quantitative", "published_at": "2026-07-11T14:09:32", "published_display": "11 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics (ABCL) TD Cowen 46th Annual Health Care Conference Summary", "summary": "AbCellera Biologics (ABCL) presented at the TD Cowen 46th Annual Health Care Conference, highlighting its evolution from a technology platform to a biotech company with end-to-end capabilities, backed by over $1 billion in investment. The company detailed its strategic pipeline, ", "url": "https://quartr.com/events/abcellera-biologics-inc-abcl-td-cowen-46th-annual-health-care-conference_3gd5pWcL", "source_name": "Quartr", "published_at": "2026-07-09T11:12:50", "published_display": "09 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics (ABCL) Q4 2024 earnings summary", "summary": "AbCellera Biologics (ABCL) reported its Q4 2024 earnings, highlighting a strategic shift from a platform/partnership model to a clinical-stage biotech. The company is advancing two lead programs, ABCL635 and ABCL575, towards clinical trials in Q2 2025, and ended 2024 with over $8", "url": "https://quartr.com/events/abcellera-biologics-inc-abcl-q4-2024_3gd5IKwc", "source_name": "Quartr", "published_at": "2026-07-09T00:09:32", "published_display": "09 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics (ABCL) Stifel 2025 Healthcare Conference Summary", "summary": "AbCellera Biologics (ABCL) has transitioned from a platform-focused partnership model to developing wholly owned clinical assets, with two assets now in the clinic and a third in IND-enabling studies. The company is primarily focused on its internal pipeline, including ABCL635 fo", "url": "https://quartr.com/events/abcellera-biologics-inc-abcl-stifel-2025-healthcare-conference_3gd5p6PL", "source_name": "Quartr", "published_at": "2026-07-08T11:40:44", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target Is $11", "summary": "Benchmark has upgraded AbCellera Biologics (ABCL) from a Hold rating to a Buy rating, setting a new price target of $11. This revision indicates a positive outlook from the analyst firm regarding the company's future stock performance.", "url": "https://www.moomoo.com/news/post/72583687/benchmark-upgrades-abcellera-biologics-to-buy-from-hold-price-target", "source_name": "Moomoo", "published_at": "2026-07-08T11:40:15", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026", "summary": "AbCellera (Nasdaq: ABCL) announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026. The company will also host an earnings conference call on the same day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast and repl", "url": "https://www.biospace.com/press-releases/abcellera-to-report-second-quarter-2026-financial-results-on-august-5-2026", "source_name": "BioSpace", "published_at": "2026-07-08T03:39:37", "published_display": "08 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics Price Target Announced at $11.00/Share by Benchmark", "summary": "Benchmark has set a price target of $11.00 per share for AbCellera Biologics (ABCL). This target suggests a potential upside for the stock from its current trading levels.", "url": "https://www.moomoo.com/news/post/72584823/abcellera-biologics-price-target-announced-at-11-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T23:39:38", "published_display": "07 Jul 2026 23:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026", "summary": "AbCellera (Nasdaq: ABCL) announced it will release its second-quarter 2026 financial results on August 5, 2026. The company will host a conference call and webcast to discuss the results and provide a business update. A replay of the webcast will be available for 90 days.", "url": "https://www.moomoo.com/news/post/72607466/press-release-abcellera-to-report-second-quarter-2026-financial-results?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T22:10:56", "published_display": "07 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/looking-top-momentum-pick-why-160005705.html", "source_name": "Zacks", "published_at": "2026-07-07T16:00:05+00:00", "published_display": "07 Jul 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera sets Aug. 5 call for Q2 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTmFpVDBKbzFqNWY0UkxCTWlNOGk2RlJPb2VtZ1o3dXNWMDNSbnZlbWJKWXBmMDM2WTZWWGZIXzBQSkFxSzVRbjAzSFBqdXM4ZnBVVGhaenRrcm5vOHVMcHhaajlnQXA3dkdoSmhPYmJ1ZENwb2l2am5aRWF5N0hEVVRLeUp2NEpjMktyZGt0SXdHNm9UZl9fUFdaSDlRNS1QdmYwSjllWnd3TWVfaURabU9mSTA2eFFBVzd4SDVwaEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What AbCellera Biologics (ABCL)'s New Oncology Veteran Director Means For Shareholders", "summary": "AbCellera Biologics (ABCL) has appointed Dr. Lynn Seely, an oncology veteran, to its Board of Directors, bringing extensive experience in late-stage drug development and commercialization. While this strengthens the company's expertise in oncology, it doesn't immediately change t", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/what-abcellera-biologics-abcls-new-oncology-veteran-director", "source_name": "Simply Wall Street", "published_at": "2026-07-07T07:40:57", "published_display": "07 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] AbCellera Biologics Inc. Insider Trading Activity", "summary": "AbCellera Biologics Inc. director Lynn Seely was granted 152,207 share options with an exercise price of $7.85 per share, expiring on July 1, 2036. These options will vest in three equal annual installments starting July 1, 2027, conditional on her continued service. The Form 4 f", "url": "https://www.stocktitan.net/sec-filings/ABCL/form-4-ab-cellera-biologics-inc-insider-trading-activity-41c4bd58b215.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:40:57", "published_display": "06 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera (ABCL) director Lynn Seely submits initial Form 3 insider ownership filing", "summary": "AbCellera Biologics Inc. director Lynn Seely has filed an initial Form 3, which is a statement of beneficial ownership for insiders. The filing indicates no reported transactions or derivative positions, establishing her status as a reporting person. This form serves as an initia", "url": "https://www.stocktitan.net/sec-filings/ABCL/form-3-ab-cellera-biologics-inc-initial-statement-of-beneficial-owner-487291578e52.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:40:57", "published_display": "06 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dr. Lynn Seely joins AbCellera (NASDAQ: ABCL) board as independent director", "summary": "AbCellera Biologics Inc. (NASDAQ: ABCL) has appointed Dr. Lynn Seely as a new Class III independent director to its Board of Directors, effective June 30, 2026. Dr. Seely brings extensive biopharmaceutical executive experience, having previously served as president and CEO of Lye", "url": "https://www.stocktitan.net/sec-filings/ABCL/8-k-ab-cellera-biologics-inc-reports-material-event-ab449337dcc9.html", "source_name": "Stock Titan", "published_at": "2026-07-06T18:40:17", "published_display": "06 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lynn Seely appointed to AbCellera Board as Class III director", "summary": "AbCellera has appointed Lynn Seely as a Class III director, effective June 30, 2026. She will serve until the 2029 annual meeting and has been deemed independent under NASDAQ and company guidelines. Seely will participate in the Non-Employee Director Compensation Policy but has n", "url": "https://www.tradingview.com/news/tradingview:44f8421d4e84f:0-lynn-seely-appointed-to-abcellera-board-as-class-iii-director/", "source_name": "TradingView", "published_at": "2026-07-06T18:40:17", "published_display": "06 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Appoints Dr. Lynn Seely to its Board of Directors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/abcellera-appoints-dr-lynn-seely-130000036.html", "source_name": "Business Wire", "published_at": "2026-07-06T13:00:00+00:00", "published_display": "06 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera appoints Lynn Seely to board of directors", "summary": "AbCellera Biologics Inc. has appointed Lynn Seely, M.D., to its board of directors as an independent director. Seely brings extensive experience from her roles as CEO of Lyell Immunopharma Inc., former CEO of Myovant Sciences Inc., and CMO of Medivation Inc., where she oversaw th", "url": "https://www.investing.com/news/company-news/abcellera-appoints-lynn-seely-to-board-of-directors-93CH-4776662", "source_name": "Investing.com", "published_at": "2026-07-06T13:40:17", "published_display": "06 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Abcellera Biologics Inc. (ABCL)", "summary": "This article analyzes the historical performance of a $1,000 investment in Abcellera Biologics Inc. (ABCL) over various periods, showing significant volatility with a 101.2% return over one year but a -58.7% return over five years. It also provides a detailed overview of AbCeller", "url": "https://www.stocktitan.net/tools/stock-return-calculator/ABCL", "source_name": "Stock Titan", "published_at": "2026-07-06T03:39:16", "published_display": "06 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost", "summary": "AbCellera Biologics (ABCL) shares experienced their best week since February, rising 18% due to anticipation of first-quarter 2026 earnings and crucial early-stage clinical data for its lead candidate, ABCL635. ABCL635 is designed as a non-hormonal treatment for menopause-related", "url": "https://stocktwits.com/news-articles/markets/equity/abcl-stock-clocks-best-week-since-february-on-clinical-data-anticipation-baker-bros-stake-boost/cZX37RpRegA", "source_name": "Stocktwits", "published_at": "2026-07-05T10:12:30", "published_display": "05 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AbCellera Biologics (ABCL) One of the Best Stocks with Biggest Upside?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNZU5tZHV1ZW5NWi1KazZIQUw1ZUJ5dzdROXc0d19RbnQyT05KXzFXV2R0SS1IcmVfb0dXakY0b09fVDRnRGtQVTJJQ01sWUdudVhTd1dnZWJsdTdIMHBSYXFQQjZWNVFfS2UzeWJHQU5DcjVkOUdCSGc5eXc0M1QxR1c1QmFDUTUzdHRLNTRHSmE4UjBGNS1Ld2NrT3A5Mlk?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics (ABCL) Could Be 22% Undervalued After Jazz Cancer Partnership", "summary": "AbCellera Biologics (ABCL) is gaining attention after a preclinical collaboration with Jazz Pharmaceuticals to develop T cell engaging multispecific antibodies for gastrointestinal cancers. Despite a significant share price increase of 132.66% over the past year, analysts believe", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-biologics-abcl-could-be-22-undervalued-after-jazz", "source_name": "Simply Wall Street", "published_at": "2026-06-30T21:39:13", "published_display": "30 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPcWctSk9ZUjRtTy1MSmVBb2RUbWJlVko0cWtacVdISFJGMjczbFRZS0Ftdm9NMG05andyQ1h3cHgzZFU5VmxJOTZOYVdUNmlwNkc0eEtXb09FN3d3VVRfOGk0WHdEcGFBeWM4c3gxS0ZudnRHanpyQ1BSSjEwZU9GQUZfdDRVWDdTWGFZOXJvd0FaVV9ZOTRsVHlB?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera (NASDAQ: ABCL) inks Jazz cancer antibody pact with $56M upfront, big milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNMVFpMXg2VU1sdWhwV0pXbHBfeXppcmtiTFNnZHRTY3d5b2pmYldqY0d4UkkwazdfdjRMbFFtUVFmV2FmNUpheHlQdWVPWjRqQ3JacWZvU2tYVXVRblpFcTExWHNkRTdmeUdmWEVFUVVFdm5LZlVwcWlmbE83a1laU3NDMzFDSWNMMkJWamczS2NZS2pTcEJGVEo2cktBV3lNOU13eWI5NGU3czFCSnZYUDgzNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ABCELLERA BIOLG (ABCL) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc3hJbGFYVHUwS1JjRmdNOXYtemp4N1RYaW1MNl85RHBraWpDczFna2RoR05EZzhtV0xTbTVsVkZHXzg4TDBGU2t0Vm1VeFpqclBzNllBMnJLMWo1R1IzdkxlVWZkNy11Vks5WWxKMFI3TkREblYxMEZHcTNHRkwwX2cxQjcydFNWZ1F3R1RmVmRpYXo4aTZwMExtM2YxQWVxd2Itd0tfVjE?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera (NASDAQ: ABCL) shareholders back directors, auditor and Say-on-Pay", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZDdOb2lTNDM5eVR4RlJhZ1ZDejhMbjVfZjRfX0l3blpBeFdxWlg0bmo3TE9Vald6NU9XckU1ZXlPdzFUa1hNQjRqbnR0UG9pbzV0XzlubFNMTWNLaFdqN19CanJaanRwT3l6b1ZNWFJWNlY1ZVdVTjJ1WGxvOWhkQWU0TkFLa29rSzVvbGgtUnFCRW1OY3pJaHBySGhodGRrU2M3ekIxWkVrVHRsVU9waHUzQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell (NASDAQ:ABCL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOMlFHX2JNOG5lQ3BPS2Y5VTlVWERQT3NSWmJiX1YyY2Zsb3h1cmhwMFhNaVNROEJRTmNZYkpPZDFsNFRkaTN5bHBHc0oyX1R6Rzc1eTBEUmtpVGVDUkw4SXB5RUxEaUwtaENyOVo4dVliWV91ZTdyYThNTjZxMjNzQ2t4dnQyOVc3R2hZdUppZFZ2NGlONG5RaDM2QmNBX0ppckJLZG1nYjJzYmVxNWJ5WXJn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Progress And Strong Q1 Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQOHk1ZVdnbmVTSko5aE1YbG9OSkxHaWp5SlRtUl9lY0hYVW1kdXF2YXd0YXd3YXgwaU5UcGsyYnNUQU1xaE1pNmJvN2JEbVo4QUx1NGZsX0Vac1hnSDJlMW1yQm1YQ0V6LWJPbjhhRGhYOTExblA4cEFsZDN0WkRCX3B1ak9qc3dkYTlRT2IxUzV6QzNjYllCb1BKVWJhV05oQUdHcTBnSQ?oc=5", "source_name": "Market source", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQd045RXg3RmcxZU5wc0c3V1dWSjlhSWUtN3RPcjJHN21GaXhHOVY0SGFOa1dxMFJfQWNucXc4c0pZSURRLUh3c3ZkeXpxUUpUVm9Zdzl5a1c5QjVOZUdLN3pIMmtWUW54YUg3SVNSRXpSN3YxTFRuNmlUS0xGZTNKSUw1cmRuV2tYZVhwRzAzcmJldVdSb0hEWFBPMS1rdEIwd1RiRkdETjRMWFM4U2VsakNSbmNpVWV3UmlUc2Q1V2hqWmRQdUNCTFY1TlZnaTRpaUl3?oc=5", "source_name": "TradingView", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOdlNxdXFTV1BxUUdGM3gzME94MjhJckpoMlVvblNnM2xnbzlYb1RYMG02MVNkbjJHcGxTZ3FoOVRYZWU0djFRTEc1T0V0TExSemZkVTdUR3ZvdjNmQnRqTTNta2tVU2RJa0NjaHVyNi1RM2toUVlQdVUtZ0RSVnlNR3VmY1BLLV9SRU5palNsd2czMmMwRmhhaUNMcjdyVE91Z3RxMXhFMA?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why AbCellera (ABCL) is Among the 10 Best Penny Stocks to Buy for Long Term", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQa1BmRUE0VHV6cDREZFc1dTdSSFRHY0g2SDFRaGJHZjhkakNHaGY4a0l0Z21YdVZ4bjMzd0lsM3pUeDFKdmxSWERRV0VoMnJfdHR6MHRzZDZjYnRXYUtRVHE2X2hoSXFfcTYzU2ZIcU1wa2R6dzhnTFhPWTNvT3pPN3hla2VlWHNnRElsWHpQb01kdEtrUlh3?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AbCellera Biologics (ABCL) Q4 Revenue Surge Tests High 20.1x P/S Growth Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxONHpsTTQzSXo1czRZN3ZyN2sxWVplcVd0bGh3cVE5STF1aGszR0VLU2docTJKUm84bXRDb1lnQ3pIYzZUeHRpUXB4RThmeEpRcGE1cHRjREp1cjR3Zm5JNnBrWVRpdzBOblBoekpxWVFadVZFMW9xWUtqOUVTekRkUG9NOFlVZzhXR0NuZEVsejdGenZhNjlsUWJIOXAzZnNhTEc5WEtUM1E?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AbCellera Biologics Among 3 Promising Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNeFR1M3M5NEF1Yk9XZnIwbUVHVFVjNV96YUFKWmxuVDBpbGJFRERpZmYwUldST1c4Y2NmaG5HMWdhWHJCNUdEN2pyTkt2YUp1ck1zRndjdWtHZHVjLVpheEphWXA5NXJDQW02N2Z5c3lsQVRWeGlxNGZxcFNFaGRubjFlaU9DaVp1QWp2MEpuZ3R6eksxT2szQ2xsRXR2VHpuaGJBQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "JonesResearch Initiates Coverage of AbCellera Biologics Inc. (ABCL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaDlDNnN4UmxkMThodC1reXcxLU9NMS1rSmhvNExmV2llT3hHZWJ6YjBhY3R2XzZhdGZEVHNQc0dLTDEyVkFmSEpfRXktYWlXTXNJWVpKRGYwRVNDamcySDVBQnQ5SU9ZUExab0tuNlNFM2FOZkZDSmJ1bmVKYm02OTJtVTVYcGdkRzZGVlFBbE1ucUhUTGc1WDRWb0pQaWVWeGJMRTFIVExQRUJCekZfNkFlbHN6c2Jm?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera (ABCL): Among the Stocks That Could 10x Over the Next 5 Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNcmJ2QU9vUktZdmZTaXVuQWQyOWQ3QnNMd3h5cnBQVnVGclgzYU1fZlNjSzJRVWxRWk5UOGROQTNKNFhWTzI4UGRqRWZEb1Q2Sk14cUw2eS1Uei1pbnMzUkFrbmxOZ1Y5bkpESThqRkRsVUtTcXltMU1YbGF3SG53ZmVVQXVCZWQ2Sk5qWkxObkY5Z3ZBd1VHSHQ5UWpMb3c?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AbCellera Biologics Inc. (ABCL): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPY1VIQ0VvTERVZkpndnFIeGVkVTZYTWgteDRmRGF3X2xzU3J2V1JuZk51MkNBQWxVYmQxRVNWV3lRWlNpOW9BWkNQdndyWEMyMWxvRzh4Rk9USEtBVnVBWjVxclQ0ZkI2UDZMa1hyOERKRTlMalBpZTJKUUQ0cEE0MzFQcDFSdw?oc=5", "source_name": "Market source", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQTWxlSFl1cmJHcmlDMWpQcE4wQUNpWW9UOXBMYTF0cUFRcTFvQ2s5UXBuX1lCaTczTlN1S1kwcGo5M0JKUHpMeW90dDNtVG85UlhSbDBsMGRxVmpPOUhxTFZ1azA4TVh4UjVveUtJNFFnM1E5Z0hMdEZ0M2xDcEhKWF8yLWN3dGthcnc?oc=5", "source_name": "Market source", "published_at": "2025-09-30T07:00:00+00:00", "published_display": "30 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics Inc. (ABCL) stock price, news, quote and history", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTFAwS1ZDd1J2T2p3MllUZTlmdXZ3bERJM01tZGtfSEVlN1FLYWxKNnJENFc4WjJDYjBZUUg5OUVoNEltenJSaUp1M0U5dk9UMWZOTUE?oc=5", "source_name": "Market source", "published_at": "2020-12-19T16:10:02+00:00", "published_display": "19 Dec 2020 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ABCL|Abcellera Biologics Inc|Price:5.665|Chg%:-0.065", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1oTUcycGo4dE5IZXV3aGstaHV2RkdlV3NNOHFDZDZoR09USTlXelJfSmNOcWhSdFJHc1pHdHVpMkY3Rk55Yks5TmZzSWdMd1NCYXN1bVp5Tk9lZw?oc=5", "source_name": "TradingKey", "published_at": "2026-07-24T09:10:31+00:00", "published_display": "24 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abcellera Biologics, Inc. (ABCL) Q1 2025 Earnings Report - Results, Call & Slides", "summary": "Abcellera Biologics (ABCL) released its Q1 2025 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -$0.15 against a consensus of -$0.14, and actual revenue of $4.24 million versus an expected $7.24 million, representing a 57.45% year", "url": "https://www.tipranks.com/stocks/abcl/earnings/q1-2025-report", "source_name": "TipRanks", "published_at": "2026-07-23T01:10:56", "published_display": "23 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abcellera Biologics, Inc. (8QQ) Q3 2025 Earnings Report - Results, Call & Slides", "summary": "Abcellera Biologics (8QQ) released its Q3 2025 earnings report, missing consensus EPS estimates by \u20ac0.04 with an actual EPS of -\u20ac0.17 versus an expected -\u20ac0.12. However, the company beat revenue expectations, reporting \u20ac7.85M against an expected \u20ac5.55M, representing a 37.62% year", "url": "https://www.tipranks.com/stocks/de:8qq/earnings/q3-2025-report", "source_name": "TipRanks", "published_at": "2026-07-21T23:09:40", "published_display": "21 Jul 2026 23:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abcellera Biologics, Inc. (8QQ) Q3 2024 Earnings Report - Results, Call & Slides", "summary": "Abcellera Biologics (8QQ) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -\u20ac0.15 against a consensus of -\u20ac0.11 and actual revenue of \u20ac5.70M compared to an expected \u20ac6.73M. The Q3 2024 earnings call was scheduled for No", "url": "https://www.tipranks.com/stocks/de:8qq/earnings/q3-2024-report", "source_name": "TipRanks", "published_at": "2026-07-21T22:41:04", "published_display": "21 Jul 2026 22:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does AbCellera\u2019s New Board Appointment Reframe Its Execution Story for Investors in ABCL?", "summary": "AbCellera Biologics announced the appointment of Lynn Seely, M.D., to its Board of Directors, bringing extensive experience in clinical development and commercialization, particularly in oncology. This appointment is expected to strengthen AbCellera's board-level expertise, align", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/does-abcelleras-new-board-appointment-reframe-its-execution", "source_name": "Simply Wall Street", "published_at": "2026-07-20T06:10:07", "published_display": "20 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11", "summary": "Cantor Fitzgerald has reiterated an Overweight rating and an $11.00 price target for AbCellera Biologics (NASDAQ:ABCL). The firm anticipates positive Phase 2 data for AbCellera's anti-NK3R antibody ABCL635 in Q3 2026, expecting favorable comparisons to approved inhibitors and a s", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-overweight-on-abcellera-stock-at-11-93CH-4798694", "source_name": "Investing.com", "published_at": "2026-07-18T14:40:27", "published_display": "18 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11 By Investing.com", "summary": "Cantor Fitzgerald has reiterated an Overweight rating and an $11 price target on AbCellera Biologics (NASDAQ:ABCL). The firm anticipates positive Phase 2 data for AbCellera's anti-NK3R antibody ABCL635 in treating vasomotor symptoms in menopause, projecting significant upside for", "url": "https://ng.investing.com/news/stock-market-news/cantor-fitzgerald-reiterates-overweight-on-abcellera-stock-at-11-93CH-2605417", "source_name": "Investing.com Nigeria", "published_at": "2026-07-18T02:39:24", "published_display": "18 Jul 2026 02:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFB5aUM2X0RTcUtleVByb05SSzAwVmRPWUxFZWJaZXgta2ZyU3VmSHY4UXFzZnd6UXppNzlNdDl3dzJyTFkwNWYyYlRJNnBIcXBqRW9mLTQ1S29Wd3c?oc=5", "source_name": "ChartMill", "published_at": "2026-07-18T00:24:07+00:00", "published_display": "18 Jul 2026 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13", "summary": "JonesTrading has reiterated its Buy rating for AbCellera Biologics (ABCL.US), maintaining a target price of $13. This indicates continued confidence from the analyst firm in the company's stock performance.", "url": "https://www.moomoo.com/news/post/73030276/jonestrading-maintains-abcellera-biologics-abclus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-16T14:10:55", "published_display": "16 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABCL Stock Price and Chart \u2014 NASDAQ:ABCL", "summary": "This article provides an overview of AbCellera Biologics Inc. (ABCL) stock, including its current price, market capitalization, key financial stats, and recent performance. It highlights the company's role as an AI-biotech firm specializing in therapeutic antibody discovery and i", "url": "https://www.tradingview.com/symbols/NASDAQ-ABCL/", "source_name": "TradingView", "published_at": "2026-07-14T13:40:13", "published_display": "14 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Weekly Recap: Lynn Seely board appointment and Benchmark upgrade to Buy", "summary": "AbCellera Biologics (ABCL) has appointed Lynn Seely to its board as a Class III director, effective June 30, 2026. Concurrently, Benchmark upgraded the stock to Buy with an $11 target price. The company is set to report its Q2 2026 results on August 5, 2026, followed by an earnin", "url": "https://www.tradingview.com/news/tradingview:4d3fd946dd5a3:0-weekly-recap-lynn-seely-board-appointment-and-benchmark-upgrade-to-buy/", "source_name": "TradingView", "published_at": "2026-07-13T11:40:41", "published_display": "13 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics Stock (ABCL) Opinions on Jazz Partnership and Analyst Upgrade", "summary": "The article discusses positive sentiment surrounding AbCellera Biologics (ABCL) due to its partnership with Jazz Pharmaceuticals and a recent analyst upgrade. Key catalysts include upcoming Phase 2 data for ABCL635 and new executive hires. Insider buying activity and increased in", "url": "https://www.quiverquant.com/news/AbCellera+Biologics+Stock+%28ABCL%29+Opinions+on+Jazz+Partnership+and+Analyst+Upgrade", "source_name": "Quiver Quantitative", "published_at": "2026-07-11T14:09:32", "published_display": "11 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics (ABCL) TD Cowen 46th Annual Health Care Conference Summary", "summary": "AbCellera Biologics (ABCL) presented at the TD Cowen 46th Annual Health Care Conference, highlighting its evolution from a technology platform to a biotech company with end-to-end capabilities, backed by over $1 billion in investment. The company detailed its strategic pipeline, ", "url": "https://quartr.com/events/abcellera-biologics-inc-abcl-td-cowen-46th-annual-health-care-conference_3gd5pWcL", "source_name": "Quartr", "published_at": "2026-07-09T11:12:50", "published_display": "09 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics (ABCL) Q4 2024 earnings summary", "summary": "AbCellera Biologics (ABCL) reported its Q4 2024 earnings, highlighting a strategic shift from a platform/partnership model to a clinical-stage biotech. The company is advancing two lead programs, ABCL635 and ABCL575, towards clinical trials in Q2 2025, and ended 2024 with over $8", "url": "https://quartr.com/events/abcellera-biologics-inc-abcl-q4-2024_3gd5IKwc", "source_name": "Quartr", "published_at": "2026-07-09T00:09:32", "published_display": "09 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics (ABCL) Stifel 2025 Healthcare Conference Summary", "summary": "AbCellera Biologics (ABCL) has transitioned from a platform-focused partnership model to developing wholly owned clinical assets, with two assets now in the clinic and a third in IND-enabling studies. The company is primarily focused on its internal pipeline, including ABCL635 fo", "url": "https://quartr.com/events/abcellera-biologics-inc-abcl-stifel-2025-healthcare-conference_3gd5p6PL", "source_name": "Quartr", "published_at": "2026-07-08T11:40:44", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target Is $11", "summary": "Benchmark has upgraded AbCellera Biologics (ABCL) from a Hold rating to a Buy rating, setting a new price target of $11. This revision indicates a positive outlook from the analyst firm regarding the company's future stock performance.", "url": "https://www.moomoo.com/news/post/72583687/benchmark-upgrades-abcellera-biologics-to-buy-from-hold-price-target", "source_name": "Moomoo", "published_at": "2026-07-08T11:40:15", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026", "summary": "AbCellera (Nasdaq: ABCL) announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026. The company will also host an earnings conference call on the same day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast and repl", "url": "https://www.biospace.com/press-releases/abcellera-to-report-second-quarter-2026-financial-results-on-august-5-2026", "source_name": "BioSpace", "published_at": "2026-07-08T03:39:37", "published_display": "08 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics Price Target Announced at $11.00/Share by Benchmark", "summary": "Benchmark has set a price target of $11.00 per share for AbCellera Biologics (ABCL). This target suggests a potential upside for the stock from its current trading levels.", "url": "https://www.moomoo.com/news/post/72584823/abcellera-biologics-price-target-announced-at-11-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T23:39:38", "published_display": "07 Jul 2026 23:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026", "summary": "AbCellera (Nasdaq: ABCL) announced it will release its second-quarter 2026 financial results on August 5, 2026. The company will host a conference call and webcast to discuss the results and provide a business update. A replay of the webcast will be available for 90 days.", "url": "https://www.moomoo.com/news/post/72607466/press-release-abcellera-to-report-second-quarter-2026-financial-results?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T22:10:56", "published_display": "07 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/looking-top-momentum-pick-why-160005705.html", "source_name": "Zacks", "published_at": "2026-07-07T16:00:05+00:00", "published_display": "07 Jul 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera sets Aug. 5 call for Q2 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTmFpVDBKbzFqNWY0UkxCTWlNOGk2RlJPb2VtZ1o3dXNWMDNSbnZlbWJKWXBmMDM2WTZWWGZIXzBQSkFxSzVRbjAzSFBqdXM4ZnBVVGhaenRrcm5vOHVMcHhaajlnQXA3dkdoSmhPYmJ1ZENwb2l2am5aRWF5N0hEVVRLeUp2NEpjMktyZGt0SXdHNm9UZl9fUFdaSDlRNS1QdmYwSjllWnd3TWVfaURabU9mSTA2eFFBVzd4SDVwaEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What AbCellera Biologics (ABCL)'s New Oncology Veteran Director Means For Shareholders", "summary": "AbCellera Biologics (ABCL) has appointed Dr. Lynn Seely, an oncology veteran, to its Board of Directors, bringing extensive experience in late-stage drug development and commercialization. While this strengthens the company's expertise in oncology, it doesn't immediately change t", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/what-abcellera-biologics-abcls-new-oncology-veteran-director", "source_name": "Simply Wall Street", "published_at": "2026-07-07T07:40:57", "published_display": "07 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] AbCellera Biologics Inc. Insider Trading Activity", "summary": "AbCellera Biologics Inc. director Lynn Seely was granted 152,207 share options with an exercise price of $7.85 per share, expiring on July 1, 2036. These options will vest in three equal annual installments starting July 1, 2027, conditional on her continued service. The Form 4 f", "url": "https://www.stocktitan.net/sec-filings/ABCL/form-4-ab-cellera-biologics-inc-insider-trading-activity-41c4bd58b215.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:40:57", "published_display": "06 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera (ABCL) director Lynn Seely submits initial Form 3 insider ownership filing", "summary": "AbCellera Biologics Inc. director Lynn Seely has filed an initial Form 3, which is a statement of beneficial ownership for insiders. The filing indicates no reported transactions or derivative positions, establishing her status as a reporting person. This form serves as an initia", "url": "https://www.stocktitan.net/sec-filings/ABCL/form-3-ab-cellera-biologics-inc-initial-statement-of-beneficial-owner-487291578e52.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:40:57", "published_display": "06 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dr. Lynn Seely joins AbCellera (NASDAQ: ABCL) board as independent director", "summary": "AbCellera Biologics Inc. (NASDAQ: ABCL) has appointed Dr. Lynn Seely as a new Class III independent director to its Board of Directors, effective June 30, 2026. Dr. Seely brings extensive biopharmaceutical executive experience, having previously served as president and CEO of Lye", "url": "https://www.stocktitan.net/sec-filings/ABCL/8-k-ab-cellera-biologics-inc-reports-material-event-ab449337dcc9.html", "source_name": "Stock Titan", "published_at": "2026-07-06T18:40:17", "published_display": "06 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lynn Seely appointed to AbCellera Board as Class III director", "summary": "AbCellera has appointed Lynn Seely as a Class III director, effective June 30, 2026. She will serve until the 2029 annual meeting and has been deemed independent under NASDAQ and company guidelines. Seely will participate in the Non-Employee Director Compensation Policy but has n", "url": "https://www.tradingview.com/news/tradingview:44f8421d4e84f:0-lynn-seely-appointed-to-abcellera-board-as-class-iii-director/", "source_name": "TradingView", "published_at": "2026-07-06T18:40:17", "published_display": "06 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Appoints Dr. Lynn Seely to its Board of Directors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/abcellera-appoints-dr-lynn-seely-130000036.html", "source_name": "Business Wire", "published_at": "2026-07-06T13:00:00+00:00", "published_display": "06 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera appoints Lynn Seely to board of directors", "summary": "AbCellera Biologics Inc. has appointed Lynn Seely, M.D., to its board of directors as an independent director. Seely brings extensive experience from her roles as CEO of Lyell Immunopharma Inc., former CEO of Myovant Sciences Inc., and CMO of Medivation Inc., where she oversaw th", "url": "https://www.investing.com/news/company-news/abcellera-appoints-lynn-seely-to-board-of-directors-93CH-4776662", "source_name": "Investing.com", "published_at": "2026-07-06T13:40:17", "published_display": "06 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Abcellera Biologics Inc. (ABCL)", "summary": "This article analyzes the historical performance of a $1,000 investment in Abcellera Biologics Inc. (ABCL) over various periods, showing significant volatility with a 101.2% return over one year but a -58.7% return over five years. It also provides a detailed overview of AbCeller", "url": "https://www.stocktitan.net/tools/stock-return-calculator/ABCL", "source_name": "Stock Titan", "published_at": "2026-07-06T03:39:16", "published_display": "06 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost", "summary": "AbCellera Biologics (ABCL) shares experienced their best week since February, rising 18% due to anticipation of first-quarter 2026 earnings and crucial early-stage clinical data for its lead candidate, ABCL635. ABCL635 is designed as a non-hormonal treatment for menopause-related", "url": "https://stocktwits.com/news-articles/markets/equity/abcl-stock-clocks-best-week-since-february-on-clinical-data-anticipation-baker-bros-stake-boost/cZX37RpRegA", "source_name": "Stocktwits", "published_at": "2026-07-05T10:12:30", "published_display": "05 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AbCellera Biologics (ABCL) One of the Best Stocks with Biggest Upside?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNZU5tZHV1ZW5NWi1KazZIQUw1ZUJ5dzdROXc0d19RbnQyT05KXzFXV2R0SS1IcmVfb0dXakY0b09fVDRnRGtQVTJJQ01sWUdudVhTd1dnZWJsdTdIMHBSYXFQQjZWNVFfS2UzeWJHQU5DcjVkOUdCSGc5eXc0M1QxR1c1QmFDUTUzdHRLNTRHSmE4UjBGNS1Ld2NrT3A5Mlk?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics (ABCL) Could Be 22% Undervalued After Jazz Cancer Partnership", "summary": "AbCellera Biologics (ABCL) is gaining attention after a preclinical collaboration with Jazz Pharmaceuticals to develop T cell engaging multispecific antibodies for gastrointestinal cancers. Despite a significant share price increase of 132.66% over the past year, analysts believe", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-biologics-abcl-could-be-22-undervalued-after-jazz", "source_name": "Simply Wall Street", "published_at": "2026-06-30T21:39:13", "published_display": "30 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPcWctSk9ZUjRtTy1MSmVBb2RUbWJlVko0cWtacVdISFJGMjczbFRZS0Ftdm9NMG05andyQ1h3cHgzZFU5VmxJOTZOYVdUNmlwNkc0eEtXb09FN3d3VVRfOGk0WHdEcGFBeWM4c3gxS0ZudnRHanpyQ1BSSjEwZU9GQUZfdDRVWDdTWGFZOXJvd0FaVV9ZOTRsVHlB?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera (NASDAQ: ABCL) inks Jazz cancer antibody pact with $56M upfront, big milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNMVFpMXg2VU1sdWhwV0pXbHBfeXppcmtiTFNnZHRTY3d5b2pmYldqY0d4UkkwazdfdjRMbFFtUVFmV2FmNUpheHlQdWVPWjRqQ3JacWZvU2tYVXVRblpFcTExWHNkRTdmeUdmWEVFUVVFdm5LZlVwcWlmbE83a1laU3NDMzFDSWNMMkJWamczS2NZS2pTcEJGVEo2cktBV3lNOU13eWI5NGU3czFCSnZYUDgzNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ABCELLERA BIOLG (ABCL) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc3hJbGFYVHUwS1JjRmdNOXYtemp4N1RYaW1MNl85RHBraWpDczFna2RoR05EZzhtV0xTbTVsVkZHXzg4TDBGU2t0Vm1VeFpqclBzNllBMnJLMWo1R1IzdkxlVWZkNy11Vks5WWxKMFI3TkREblYxMEZHcTNHRkwwX2cxQjcydFNWZ1F3R1RmVmRpYXo4aTZwMExtM2YxQWVxd2Itd0tfVjE?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera (NASDAQ: ABCL) shareholders back directors, auditor and Say-on-Pay", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZDdOb2lTNDM5eVR4RlJhZ1ZDejhMbjVfZjRfX0l3blpBeFdxWlg0bmo3TE9Vald6NU9XckU1ZXlPdzFUa1hNQjRqbnR0UG9pbzV0XzlubFNMTWNLaFdqN19CanJaanRwT3l6b1ZNWFJWNlY1ZVdVTjJ1WGxvOWhkQWU0TkFLa29rSzVvbGgtUnFCRW1OY3pJaHBySGhodGRrU2M3ekIxWkVrVHRsVU9waHUzQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell (NASDAQ:ABCL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOMlFHX2JNOG5lQ3BPS2Y5VTlVWERQT3NSWmJiX1YyY2Zsb3h1cmhwMFhNaVNROEJRTmNZYkpPZDFsNFRkaTN5bHBHc0oyX1R6Rzc1eTBEUmtpVGVDUkw4SXB5RUxEaUwtaENyOVo4dVliWV91ZTdyYThNTjZxMjNzQ2t4dnQyOVc3R2hZdUppZFZ2NGlONG5RaDM2QmNBX0ppckJLZG1nYjJzYmVxNWJ5WXJn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Progress And Strong Q1 Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQOHk1ZVdnbmVTSko5aE1YbG9OSkxHaWp5SlRtUl9lY0hYVW1kdXF2YXd0YXd3YXgwaU5UcGsyYnNUQU1xaE1pNmJvN2JEbVo4QUx1NGZsX0Vac1hnSDJlMW1yQm1YQ0V6LWJPbjhhRGhYOTExblA4cEFsZDN0WkRCX3B1ak9qc3dkYTlRT2IxUzV6QzNjYllCb1BKVWJhV05oQUdHcTBnSQ?oc=5", "source_name": "Market source", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQd045RXg3RmcxZU5wc0c3V1dWSjlhSWUtN3RPcjJHN21GaXhHOVY0SGFOa1dxMFJfQWNucXc4c0pZSURRLUh3c3ZkeXpxUUpUVm9Zdzl5a1c5QjVOZUdLN3pIMmtWUW54YUg3SVNSRXpSN3YxTFRuNmlUS0xGZTNKSUw1cmRuV2tYZVhwRzAzcmJldVdSb0hEWFBPMS1rdEIwd1RiRkdETjRMWFM4U2VsakNSbmNpVWV3UmlUc2Q1V2hqWmRQdUNCTFY1TlZnaTRpaUl3?oc=5", "source_name": "TradingView", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOdlNxdXFTV1BxUUdGM3gzME94MjhJckpoMlVvblNnM2xnbzlYb1RYMG02MVNkbjJHcGxTZ3FoOVRYZWU0djFRTEc1T0V0TExSemZkVTdUR3ZvdjNmQnRqTTNta2tVU2RJa0NjaHVyNi1RM2toUVlQdVUtZ0RSVnlNR3VmY1BLLV9SRU5palNsd2czMmMwRmhhaUNMcjdyVE91Z3RxMXhFMA?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why AbCellera (ABCL) is Among the 10 Best Penny Stocks to Buy for Long Term", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQa1BmRUE0VHV6cDREZFc1dTdSSFRHY0g2SDFRaGJHZjhkakNHaGY4a0l0Z21YdVZ4bjMzd0lsM3pUeDFKdmxSWERRV0VoMnJfdHR6MHRzZDZjYnRXYUtRVHE2X2hoSXFfcTYzU2ZIcU1wa2R6dzhnTFhPWTNvT3pPN3hla2VlWHNnRElsWHpQb01kdEtrUlh3?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics (ABCL) Q4 Revenue Surge Tests High 20.1x P/S Growth Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxONHpsTTQzSXo1czRZN3ZyN2sxWVplcVd0bGh3cVE5STF1aGszR0VLU2docTJKUm84bXRDb1lnQ3pIYzZUeHRpUXB4RThmeEpRcGE1cHRjREp1cjR3Zm5JNnBrWVRpdzBOblBoekpxWVFadVZFMW9xWUtqOUVTekRkUG9NOFlVZzhXR0NuZEVsejdGenZhNjlsUWJIOXAzZnNhTEc5WEtUM1E?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics Among 3 Promising Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNeFR1M3M5NEF1Yk9XZnIwbUVHVFVjNV96YUFKWmxuVDBpbGJFRERpZmYwUldST1c4Y2NmaG5HMWdhWHJCNUdEN2pyTkt2YUp1ck1zRndjdWtHZHVjLVpheEphWXA5NXJDQW02N2Z5c3lsQVRWeGlxNGZxcFNFaGRubjFlaU9DaVp1QWp2MEpuZ3R6eksxT2szQ2xsRXR2VHpuaGJBQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JonesResearch Initiates Coverage of AbCellera Biologics Inc. (ABCL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaDlDNnN4UmxkMThodC1reXcxLU9NMS1rSmhvNExmV2llT3hHZWJ6YjBhY3R2XzZhdGZEVHNQc0dLTDEyVkFmSEpfRXktYWlXTXNJWVpKRGYwRVNDamcySDVBQnQ5SU9ZUExab0tuNlNFM2FOZkZDSmJ1bmVKYm02OTJtVTVYcGdkRzZGVlFBbE1ucUhUTGc1WDRWb0pQaWVWeGJMRTFIVExQRUJCekZfNkFlbHN6c2Jm?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera (ABCL): Among the Stocks That Could 10x Over the Next 5 Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNcmJ2QU9vUktZdmZTaXVuQWQyOWQ3QnNMd3h5cnBQVnVGclgzYU1fZlNjSzJRVWxRWk5UOGROQTNKNFhWTzI4UGRqRWZEb1Q2Sk14cUw2eS1Uei1pbnMzUkFrbmxOZ1Y5bkpESThqRkRsVUtTcXltMU1YbGF3SG53ZmVVQXVCZWQ2Sk5qWkxObkY5Z3ZBd1VHSHQ5UWpMb3c?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics Inc. (ABCL): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPY1VIQ0VvTERVZkpndnFIeGVkVTZYTWgteDRmRGF3X2xzU3J2V1JuZk51MkNBQWxVYmQxRVNWV3lRWlNpOW9BWkNQdndyWEMyMWxvRzh4Rk9USEtBVnVBWjVxclQ0ZkI2UDZMa1hyOERKRTlMalBpZTJKUUQ0cEE0MzFQcDFSdw?oc=5", "source_name": "Market source", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQTWxlSFl1cmJHcmlDMWpQcE4wQUNpWW9UOXBMYTF0cUFRcTFvQ2s5UXBuX1lCaTczTlN1S1kwcGo5M0JKUHpMeW90dDNtVG85UlhSbDBsMGRxVmpPOUhxTFZ1azA4TVh4UjVveUtJNFFnM1E5Z0hMdEZ0M2xDcEhKWF8yLWN3dGthcnc?oc=5", "source_name": "Market source", "published_at": "2025-09-30T07:00:00+00:00", "published_display": "30 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbCellera Biologics Inc. (ABCL) stock price, news, quote and history", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTFAwS1ZDd1J2T2p3MllUZTlmdXZ3bERJM01tZGtfSEVlN1FLYWxKNnJENFc4WjJDYjBZUUg5OUVoNEltenJSaUp1M0U5dk9UMWZOTUE?oc=5", "source_name": "Market source", "published_at": "2020-12-19T16:10:02+00:00", "published_display": "19 Dec 2020 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 60, "sentiment_summary": {"positive": 21, "negative": 4, "neutral": 35, "score": 57, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.2, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 10.31, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}], "positive_events": 21, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 6.46, "latest_week": "2026-07-17", "one_week_move": -4.9, "four_week_move": 16.9, "twelve_week_move": 55.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.331342, "market_dynamics_buy_signal": false, "relative_strength": 30.22188, "fair_value_gap": 62.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.4157, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.9% over one week, +16.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 19}, {"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "TipRanks", "count": 3}, {"label": "Simply Wall Street", "count": 3}, {"label": "Quartr", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 21}, {"label": "Analyst action", "count": 7}, {"label": "Deals and strategy", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.9% over one week, +16.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ABCL|Abcellera Biologics Inc|Price:5.665|Chg%:-0.065"}], "updated_at": "2026-07-24T14:23:19.814772+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}